https://scholars.lib.ntu.edu.tw/handle/123456789/594879| Title: | Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial | Authors: | Galle P.R. Finn R.S. Qin S. Ikeda M. Zhu A.X. Kim T.-Y. Kudo M. Breder V. Merle P. Kaseb A. Li D. Mulla S. Verret W. Xu D.-Z. Hernandez S. Ding B. Liu J. Huang C. Lim H.Y. ANN-LII CHENG Ducreux M. |
Issue Date: | 2021 | Publisher: | Lancet Publishing Group | Journal Volume: | 22 | Journal Issue: | 7 | Start page/Pages: | 991-1001 | Source: | The Lancet Oncology | Abstract: | Background: Understanding patients' experience of cancer treatment is important. We aimed to evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus sorafenib in patients with advanced hepatocellular carcinoma in the IMbrave150 |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85108809205&doi=10.1016%2fS1470-2045%2821%2900151-0&partnerID=40&md5=a1c633915becd241fc3e5b6b4fdd3d1e https://scholars.lib.ntu.edu.tw/handle/123456789/594879 |
ISSN: | 1470-2045 | DOI: | 10.1016/S1470-2045(21)00151-0 | SDG/Keyword: | alpha fetoprotein; atezolizumab; bevacizumab; sorafenib; angiogenesis inhibitor; antineoplastic agent; atezolizumab; bevacizumab; monoclonal antibody; protein kinase inhibitor; sorafenib; abdominal swelling; adult; advanced cancer; Article; body image; ca [SDGs]SDG3 |
| Appears in Collections: | 腫瘤醫學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.